整合40基因表达谱(i40-GEP)验证:为高危皮肤鳞状细胞癌提供预后及辅助放疗获益信息
该研究将5项临床病理特征与已验证的40-GEP整合为i40-GEP,在572例高危皮肤鳞状细胞癌患者中验证其风险分层能力。结果显示i40-GEP可显著分层转移和局部复发风险(P < .0001),Class 1A阴性预测值>95%,Class 2B患者3年无转移生存率最低(66.2%)且从辅助放疗中获益。
要点
- i40-GEP将患者分为1A、1B、2A、2B四类,显著分层转移和局部复发风险。
- Class 1A在NCCN各亚组中阴性预测值均>95%。
- Class 2B占12.9%,3年无转移生存率66.2%,且显示辅助放疗获益。
核心结论
- i40-GEP能准确分层高危皮肤鳞状细胞癌患者的转移和局部复发风险,改善临床决策。
- Class 2B i40-GEP识别最可能从辅助放疗中获益的患者。
研究设计与样本
- 回顾性验证研究,验证队列n=572。
- i40-GEP整合优化嵌套预测模型、5项临床病理特征(免疫抑制、部位、分化、肿瘤直径、神经侵犯)与已验证的40-GEP。
主要发现
- i40-GEP显著分层转移和局部复发风险(P < .0001)。
- Class 1A在NCCN各亚组中阴性预测值>95%。
- i40-GEP将12.9%患者归为Class 2B,其3年无转移生存率最低(66.2%),并显示辅助放疗获益。
- 多变量分析显示i40-GEP结果对转移和局部复发风险的预测显著优于单个临床病理因素。
关键数值与推荐
- 风险分类:Class 1A(低危)、Class 1B(中危)、Class 2A(高危)、Class 2B(最高危)。
临床怎么用
- 在高危皮肤鳞状细胞癌中,可结合i40-GEP进行风险分层,辅助治疗决策。
- Class 2B患者可能从辅助放疗中获益,可考虑推荐。
局限性
- 回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Risk assessment in high-risk cutaneous squamous cell carcinoma uses several clinicopathologic staging system tools, yet under- and overtreatment often occur. Integration of tumor biology as an independent predictor via gene expression profile (GEP) may improve risk stratification and tailor adjuvant care. OBJECTIVE: Integrate clinicopathologic risk factors with 40-GEP testing to refine risk stratification. METHODS: Integrated 40-GEP (i40-GEP) combines optimized nested predictive models and 5 clinicopathologic features (immunosuppression, location, differentiation, tumor diameter, and perineural invasion) with the validated 40-GEP, and reports results: Class 1A (low risk), Class 1B (moderate risk), Class 2A (high risk), and Class 2B (highest risk). RESULTS: i40-GEP significantly stratifies metastatic and local recurrence risk (P < .0001) in a validation cohort (n = 572), with >95% negative predictive value for Class 1A across National Comprehensive Cancer Network subsets. The i40-GEP identified 12.9% of patients as Class 2B, with the lowest 3-year metastasis-free survival (66.2%) and a demonstrated benefit from adjuvant radiation treatment (ART). Multivariable analysis showed i40-GEP results significantly predict metastatic and local recurrence risk more than individual clinicopathologic factors. LIMITATIONS: Retrospective study. CONCLUSIONS: i40-GEP accurately stratifies metastatic and local recurrence risk in patients with high-risk cutaneous squamous cell carcinoma, leading to improved clinical decision-making. Class 2B i40-GEP identifies patients most likely to benefit from ART.
引用
- Ratner D, Singh G, Rizzo JM, et al. Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2026. PMID: 42637048. doi:10.1016/j.jaad.2026.08.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。